Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018128973) HUMAN ANTIBODIES TO S. AUREUS HEMOLYSIN A TOXIN
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/128973 International Application No.: PCT/US2018/012044
Publication Date: 12.07.2018 International Filing Date: 02.01.2018
IPC:
C07K 16/12 (2006.01) ,A61P 31/04 (2006.01) ,A61K 39/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
12
against material from bacteria
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
04
Antibacterial agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
Applicants:
REGENERON PHARMACEUTICALS, INC. [US/US]; 777 Old Saw Mill River Road Tarrytown, New York 10591, US
Inventors:
COPPI, Alida; US
MASON, Peter; US
OLSON, William; US
Agent:
TERMES, Lance A.; US
Priority Data:
62/441,78603.01.2017US
Title (EN) HUMAN ANTIBODIES TO S. AUREUS HEMOLYSIN A TOXIN
(FR) ANTICORPS HUMAINS DIRIGÉS CONTRE LA TOXINE HÉMOLYSINE A DE S. AUREUS
Abstract:
(EN) The present invention provides antibodies that bind to Staphylococcus aureus Hemolysin A toxin, and methods of use. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Hemolysin A. The antibodies of the invention are useful for inhibiting or neutralizing Hemolysin A activity, thus providing a means of preventing or treating a Hemolysin A-related disease or disorder such as S. aureus infection. In some embodiments, the antibodies of the present invention are used in treating at least one symptom or complication of a S. aureus infection.
(FR) La présente invention concerne des anticorps qui se lient à la toxine hémolysine A de Staphylococcus aureus, et leurs procédés d'utilisation. Selon certains modes de réalisation de l'invention, les anticorps sont des anticorps entièrement humains qui se lient à l'hémolysine A et sont utiles pour inhiber ou neutraliser l'activité hémolysine A, fournissant ainsi un moyen pour prévenir ou traiter une maladie ou un trouble lié à l'hémolysine A, tel que l'infection à S. aureus. Dans d'autres modes de réalisation, les anticorps selon la présente invention sont utilisés pour traiter au moins un symptôme ou une complication d'une infection à S. aureus.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)